(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Eugene Shenderov presented results of a phase 2 trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer. B7-H3, a member of the B7 superfamily, is highly expressed (relative to PD-L1 and PD-L2) in prostate cancer. Further, its expression is prognostic as it is associated with rapid biochemical recurrence and early metastases. Enoblituzumab is an investigational humanized Fc-optimized B7-H3–targeting antibody that induces antibody-dependent cellular cytotoxicity (ADCC).